Gaucher Disease Research Highlights: ASH 2020
Jointly Provided by
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Start date: March 31, 2021
End date: March 31, 2022
NO LONGER AVAILABLE FOR CREDIT
Estimated time to complete: 0.25 hours
Activity Description
At the American Society of Hematology Annual Meeting (ASH 2020), new information and data were presented on Gaucher disease, a rare lysosomal storage disorder, that requires a team of health care professionals to properly manage. This CME activity highlights the latest information about Gaucher disease from ASH 2020 and provides expert analysis of its clinical relevance for busy members of the care team in order to help them care for patients with this rare condition.
Activity Faculty
Derralynn Hughes, MD, DPhil, FDCP, FRCPath
Professor of Experimental Haematology
University College London
Clinical Director of Research and Innovation
Royal Free London NHS Foundation Trust
United Kingdom
Target Audience
This activity has been designed to meet the educational needs of physicians caring for individuals with Gaucher disease. Other members of the care team may also participate.
Learning Objectives
After participating in the activity, learners should be better able to:
- Describe the latest research being presented to better manage people with Gaucher disease and its clinical relevance.
Accreditation and Credit Designation
In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
American Academy of CME, Inc., designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Statement
According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence.
Disclosures are as follows:
Professor Hughes discloses the following financial relationships:
Advisory Board: Amicus, Takeda, Sanofi, Idorsia, Freeline, Protalix, Biomarin Pharmaceuticals, Promotional Speakers’ Bureau: Takeda, Sanofi
Planners for this activity have no relevant financial relationships with any commercial interests.
This activity will review off-label or investigational information.
The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.
Method of Participation
There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the post-program assessment. Your certificate can be mailed to you in approximately 30 days.
Hardware/Software Requirements
Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection
Macintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection
Privacy
For more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm. For more information about CheckRare’s privacy policy, please access https://checkrare.com/privacy/
Contact
For any questions, please contact: CEServices@academycme.org
Copyright
© 2021. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).
Gaucher Disease Research Highlights: ASH 2020
References
GAUCHER DISEASE RESEARCH AT ASH 2020
Revel-Vilk S. Study Design: Development of an Advanced Machine Learning Algorithm for the Early Diagnosis of Gaucher Disease Using Real-World Data. Presented at American Society of Hematology Meeting & Exposition (Virtual Meeting): December7, 2020. #3413.
Motta I, Benedetto C, Stroppiano M, et al. High-Risk Population Screening for Gaucher Disease: Final Results and Key Learnings from an Italian Multicenter Observational Study. Blood. 2020: 136 (Suppl 1): 17–18. DOI: https://doi.org/10.1182/blood-2020-141527
Rosenbloom B. Hematologic Malignancies and Monoclonal Gammopathy of Undetermined Significance (MGUS) in Gaucher Disease Type 1 Patients in the International Cooperative Gaucher Group Gaucher Registry. Presented at American Society of Hematology Meeting & Exposition (Virtual Meeting): December 7, 2020. #3164.
Cerulli Irelli E. Multi-Parameter Neurological Study Based on Combined Conventional and Functional Assessments in Gaucher Disease Patients (SENOPRO_GAUCHER Study). Presented at American Society of Hematology Meeting & Exposition (Virtual Meeting): December 7, 2020. #3411.
El-Beshlawy A, Abd El-Azim Eid KM, AbdelSalam A, et al. Largest Cohort Study of Gaucher Disease Type 3 from a Single Center in Egypt Spanning Two Decades. Blood. 2020; 136 (Suppl1): 21–22.DOI: https://doi.org/10.1182/blood-2020-141776
GAUCHER DISEASE AND COVID
Fierro L, Nesheiwat N, Naik H et al. Gaucher disease and SARS-CoV-2 infection: Experience from 181 patients in New York. Mol Genet Metab 2021; 132: 44-48. DOI: 10.1016/j.ymgme.2020.12.288
Zimran A, Szer J, Revel-Vilk S. Impact of Gaucher disease on COVID-19. Intern Med J 2020; 50: 894-895. DOI: 10.1111/imj.14894
Jointly Provided by
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Start date: March 31, 2021
End date: March 31, 2022
NO LONGER AVAILABLE FOR CREDIT
Estimated time to complete: 0.25 hours
Activity Description
At the American Society of Hematology Annual Meeting (ASH 2020), new information and data were presented on Gaucher disease, a rare lysosomal storage disorder, that requires a team of health care professionals to properly manage. This CME activity highlights the latest information about Gaucher disease from ASH 2020 and provides expert analysis of its clinical relevance for busy members of the care team in order to help them care for patients with this rare condition.
Activity Faculty
Derralynn Hughes, MD, DPhil, FDCP, FRCPath
Professor of Experimental Haematology
University College London
Clinical Director of Research and Innovation
Royal Free London NHS Foundation Trust
United Kingdom
Target Audience
This activity has been designed to meet the educational needs of physicians caring for individuals with Gaucher disease. Other members of the care team may also participate.
Learning Objectives
After participating in the activity, learners should be better able to:
- Describe the latest research being presented to better manage people with Gaucher disease and its clinical relevance.
Accreditation and Credit Designation
In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
American Academy of CME, Inc., designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Statement
According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence.
Disclosures are as follows:
Professor Hughes discloses the following financial relationships:
Advisory Board: Amicus, Takeda, Sanofi, Idorsia, Freeline, Protalix, Biomarin Pharmaceuticals, Promotional Speakers' Bureau: Takeda, Sanofi
Planners for this activity have no relevant financial relationships with any commercial interests.
This activity will review off-label or investigational information.
The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.
Method of Participation
There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the post-program assessment. Your certificate can be mailed to you in approximately 30 days.
Hardware/Software Requirements
Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection
Macintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection
Privacy
For more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm. For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/
Contact
For any questions, please contact: CEServices@academycme.org
Copyright
© 2021. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).
